Mizuho Maintains Outperform on Iovance Biotherapeutics, Raises Price Target to $11

Mizuho analyst Mara Goldstein maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Outperform and raises the price target from $10 to $11.